SG3 Management’s DexCom DXCM Stock Holding History

SG3 Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,000	Closed	-$1.26M	–	1105
2021 Q1	$1.26M	Buy	+14,000	New	+$1.31M	0.03%	536
2018 Q2	–	Sell	-10,000	Closed	-$185K	–	124
2018 Q1	$185K	Buy	+10,000	New	+$148K	0.08%	72

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

SG3 Management's DXCM Position: Q2 2021 in Review

SG3 Management sold out of DexCom (DXCM) in Q2 2021, closing a stake of 14,000 shares — an estimated $1.26M sold.

SG3 Management first reported a position in DXCM in Q1 2018 and held it in 2 quarters. The position peaked at $1.26M in Q1 2021. 726 funds tracked by Wall St. Rank hold DXCM as of Q2 2021.

SG3 Management reported no remaining DexCom position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 14,000 DexCom shares in Q2 2021, an estimated $1.26M.
SG3 Management first reported a position in DexCom in Q1 2018 and held it in 2 quarters.
SG3 Management's DexCom position peaked at $1.26M in Q1 2021.
726 funds tracked by Wall St. Rank held DexCom as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.